{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,29]],"date-time":"2026-09-29T11:14:41Z","timestamp":1790680481622,"version":"4.1.0"},"reference-count":54,"publisher":"Springer Science and Business Media LLC","issue":"S2","license":[{"start":{"date-parts":[[2013,6,27]],"date-time":"2013-06-27T00:00:00Z","timestamp":1372291200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/2.0"},{"start":{"date-parts":[[2013,6,27]],"date-time":"2013-06-27T00:00:00Z","timestamp":1372291200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/2.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["J GEN INTERN MED"],"published-print":{"date-parts":[[2013,7]]},"abstract":"<jats:title>ABSTRACT<\/jats:title>\n          <jats:sec>\n            <jats:title>BACKGROUND<\/jats:title>\n            <jats:p>Women with diabetes have higher low-density lipoprotein (LDL) levels than men, resulting in apparent disparities between genders on quality indicators tied to LDL thresholds.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>OBJECTIVE<\/jats:title>\n            <jats:p>To investigate whether gender disparities persist when accounting for clinical action with statins or cardiovascular risk.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>DESIGN<\/jats:title>\n            <jats:p>Retrospective cohort study.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>PARTICIPANTS<\/jats:title>\n            <jats:p>Veterans Health Administration patients (21,780 women and 646,429 men) aged 50\u201375 with diabetes.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>MAIN MEASURES<\/jats:title>\n            <jats:p>Threshold measure: LDL &lt; 100\u00a0mg\/dL; clinical action measure: LDL &lt; 100\u00a0mg\/dL; or LDL \u2265 100\u00a0mg\/dL and the patient was prescribed a moderate or high-dose statin at the time of the test; or LDL \u2265 100\u00a0mg\/dL and the patient received other appropriate clinical action within 90 days; adherence: continuous multiple interval measure of gaps in dispensed medication (CMG).<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>KEY RESULTS<\/jats:title>\n            <jats:p>Women were much less likely to have LDL &lt; 100\u00a0mg\/dL than were men (55\u00a0% vs. 68\u00a0%). This disparity narrowed from 13\u00a0% to 6\u00a0% for passing the clinical action measure (79\u00a0% vs. 85\u00a0%). These gender differences persisted among those with ischemic heart disease (IHD). Women had a lower odds of passing the clinical action measure (odds ratio 0.68, 95\u00a0% confidence interval 0.66\u20130.71). Among those with IHD, the gender gap increased with age. Differences in pass rates were explained by women\u2019s higher LDL levels, but not by their slightly worse adherence (3\u00a0% higher CMG).<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>CONCLUSIONS<\/jats:title>\n            <jats:p>Women and men veterans receive more similar quality of care for lipids in diabetes than previously indicated. Less reassuringly, the remaining gender differences appear to be as common in women at high cardiovascular risk as in those at low risk. Rather than focus on simply improving LDL levels in all women with diabetes, future efforts should ensure that patients with high cardiovascular risk are appropriately treated with statins when clinically indicated, feasible, and concordant with patient preferences.<\/jats:p>\n          <\/jats:sec>","DOI":"10.1007\/s11606-013-2340-5","type":"journal-article","created":{"date-parts":[[2013,6,26]],"date-time":"2013-06-26T18:49:01Z","timestamp":1372272541000},"page":"529-535","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":31,"title":["Accounting for Clinical Action Reduces Estimates of Gender Disparities in Lipid Management for Diabetic Veterans"],"prefix":"10.1007","volume":"28","author":[{"given":"Varsha G.","family":"Vimalananda","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Donald R.","family":"Miller","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Timothy P.","family":"Hofer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Robert G.","family":"Holleman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mandi L.","family":"Klamerus","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eve A.","family":"Kerr","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2013,6,27]]},"reference":[{"issue":"1","key":"2340_CR1","doi-asserted-by":"publisher","first-page":"69","DOI":"10.2337\/dc07-1244","volume":"31","author":"A Ferrara","year":"2008","unstructured":"Ferrara A, Mangione CM, Kim C, Marrero DG, Curb D, Stevens M, et al. Sex disparities in control and treatment of modifiable cardiovascular disease risk factors among patients with diabetes: Translating Research Into Action for Diabetes (TRIAD) study. Diabetes Care. 2008;31(1):69\u201374.","journal-title":"Diabetes Care"},{"issue":"7","key":"2340_CR2","doi-asserted-by":"publisher","first-page":"1389","DOI":"10.2337\/dc08-0194","volume":"31","author":"I Gouni-Berthold","year":"2008","unstructured":"Gouni-Berthold I, Berthold HK, Mantzoros CS, Bohm M, Krone W. Sex disparities in the treatment and control of cardiovascular risk factors in type 2 diabetes. Diabetes Care. 2008;31(7):1389\u201391.","journal-title":"Diabetes Care"},{"issue":"15","key":"2340_CR3","doi-asserted-by":"publisher","first-page":"1737","DOI":"10.1001\/archinte.162.15.1737","volume":"162","author":"AM Kanaya","year":"2002","unstructured":"Kanaya AM, Grady D, Barrett-Connor E. Explaining the sex difference in coronary heart disease mortality among patients with type 2 diabetes mellitus: a meta-analysis. Arch Intern Med. 2002;162(15):1737\u201345.","journal-title":"Arch Intern Med"},{"issue":"1","key":"2340_CR4","doi-asserted-by":"publisher","first-page":"45","DOI":"10.1016\/j.puhe.2004.03.004","volume":"119","author":"V Shalev","year":"2005","unstructured":"Shalev V, Chodick G, Heymann AD, Kokia E. Gender differences in healthcare utilization and medical indicators among patients with diabetes. Public Health. 2005;119(1):45\u20139.","journal-title":"Public Health"},{"issue":"Suppl 3","key":"2340_CR5","doi-asserted-by":"publisher","first-page":"S47","DOI":"10.1111\/j.1525-1497.2006.00374.x","volume":"21","author":"CL Tseng","year":"2006","unstructured":"Tseng CL, Sambamoorthi U, Rajan M, Tiwari A, Frayne S, Findley P, et al. Are there gender differences in diabetes care among elderly Medicare enrolled veterans? J Gen Intern Med. 2006;21(Suppl 3):S47\u201353.","journal-title":"J Gen Intern Med"},{"issue":"3","key":"2340_CR6","doi-asserted-by":"publisher","first-page":"514","DOI":"10.2337\/diacare.28.3.514","volume":"28","author":"DJ Wexler","year":"2005","unstructured":"Wexler DJ, Grant RW, Meigs JB, Nathan DM, Cagliero E. Sex disparities in treatment of cardiac risk factors in patients with type 2 diabetes. Diabetes Care. 2005;28(3):514\u201320.","journal-title":"Diabetes Care"},{"issue":"8","key":"2340_CR7","doi-asserted-by":"publisher","first-page":"1467","DOI":"10.2337\/dc09-0260","volume":"32","author":"GJ Winston","year":"2009","unstructured":"Winston GJ, Barr RG, Carrasquillo O, Bertoni AG, Shea S. Sex and racial\/ethnic differences in cardiovascular disease risk factor treatment and control among individuals with diabetes in the Multi-Ethnic Study of Atherosclerosis (MESA). Diabetes Care. 2009;32(8):1467\u20139.","journal-title":"Diabetes Care"},{"issue":"4 Suppl","key":"2340_CR8","doi-asserted-by":"publisher","first-page":"S176","DOI":"10.1016\/j.whi.2011.04.009","volume":"21","author":"VG Vimalananda","year":"2011","unstructured":"Vimalananda VG, Miller DR, Palnati M, Christiansen CL, Fincke BG. Gender disparities in lipid-lowering therapy among veterans with diabetes. Womens Health Issues. 2011;21(4 Suppl):S176\u201381.","journal-title":"Womens Health Issues"},{"key":"2340_CR9","unstructured":"Wright SM, Schaefer J, Reyes-Harvey E, Francis J. Comparing the care of women and men veterans in the VA. Washington, D.C.: VA Office of Analytics and Business Intelligence White Paper to the U.S. Assistant Deputy Under Secretary for Quality and Patient Safety, Veterans Health Administration; 2012."},{"issue":"12","key":"2340_CR10","doi-asserted-by":"publisher","first-page":"938","DOI":"10.7326\/0003-4819-141-12-200412210-00010","volume":"141","author":"SM Asch","year":"2004","unstructured":"Asch SM, McGlynn EA, Hogan MM, Hayward RA, Shekelle P, Rubenstein L, et al. Comparison of quality of care for patients in the Veterans Health Administration and patients in a national sample. Ann Intern Med. 2004;141(12):938\u201345.","journal-title":"Ann Intern Med"},{"issue":"4","key":"2340_CR11","doi-asserted-by":"publisher","first-page":"272","DOI":"10.7326\/0003-4819-141-4-200408170-00007","volume":"141","author":"EA Kerr","year":"2004","unstructured":"Kerr EA, Gerzoff RB, Krein SL, Selby JV, Piette JD, Curb JD, et al. Diabetes care quality in the Veterans Affairs health care system and commercial managed care: The TRIAD study. Ann Intern Med. 2004;141(4):272\u201381.","journal-title":"Ann Intern Med"},{"issue":"8","key":"2340_CR12","doi-asserted-by":"publisher","first-page":"762","DOI":"10.1111\/j.1525-1497.2005.0160.x","volume":"20","author":"AK Jha","year":"2005","unstructured":"Jha AK, Perlin JB, Steinman MA, Peabody JW, Ayanian JZ. Quality of ambulatory care for women and men in the Veterans Affairs health care system. J Gen Intern Med. 2005;20(8):762\u20135.","journal-title":"J Gen Intern Med"},{"issue":"1","key":"2340_CR13","doi-asserted-by":"publisher","first-page":"2","DOI":"10.1161\/CIRCOUTCOMES.111.964676","volume":"5","author":"RA Hayward","year":"2012","unstructured":"Hayward RA, Krumholz HM. Three reasons to abandon low-density lipoprotein targets: an open letter to the adult treatment panel IV of the national institutes of health. Circ Cardiovasc Qual Outcomes. 2012;5(1):2\u20135.","journal-title":"Circ Cardiovasc Qual Outcomes"},{"issue":"10","key":"2340_CR14","doi-asserted-by":"publisher","first-page":"1173","DOI":"10.1097\/01.MLR.0000088453.57269.29","volume":"41","author":"EA Kerr","year":"2003","unstructured":"Kerr EA, Smith DM, Hogan MM, Hofer TP, Krein SL, Bermann M, et al. Building a better quality measure: Are some patients with \u2018poor quality\u2019 actually getting good care? Med Care. 2003;41(10):1173\u201382.","journal-title":"Med Care"},{"key":"2340_CR15","doi-asserted-by":"publisher","first-page":"520","DOI":"10.7326\/0003-4819-145-7-200610030-00010","volume":"145","author":"RA Hayward","year":"2006","unstructured":"Hayward RA, Hofer TP, Vijan S. Narrative review: lack of evidence for recommended low-density lipoprotein treatment targets: a solvable problem. Ann Intern Med. 2006;145:520\u201330.","journal-title":"Ann Intern Med"},{"issue":"2","key":"2340_CR16","doi-asserted-by":"publisher","first-page":"248","DOI":"10.1161\/CIR.0b013e31821d9ef2","volume":"124","author":"J Drozda Jr","year":"2011","unstructured":"Drozda J Jr, Messer JV, Spertus J, Abramowitz B, Alexander K, Beam CT, et al. ACCF\/AHA\/AMA-PCPI 2011 performance measures for adults with coronary artery disease and hypertension: A report of the American College of Cardiology Foundation\/American Heart Association task force on performance measures and the American Medical Association-Physician Consortium for Performance Improvement. Circulation. 2011;124(2):248\u201370.","journal-title":"Circulation"},{"key":"2340_CR17","unstructured":"Assessing quality of care for diabetes - conference final report. [Internet].: AHRQ; 2008; cited December 10, 2012]. Available from: http:\/\/www.ahrq.gov\/qual\/diabetescare\/."},{"issue":"4","key":"2340_CR18","doi-asserted-by":"publisher","first-page":"395","DOI":"10.1097\/MLR.0b013e31818d775c","volume":"47","author":"JV Selby","year":"2009","unstructured":"Selby JV, Uratsu CS, Fireman B, Schmittdiel JA, Peng T, Rodondi N, et al. Treatment intensification and risk factor control: toward more clinically relevant quality measures. Med Care. 2009;47(4):395\u2013402.","journal-title":"Med Care"},{"key":"2340_CR19","first-page":"1","volume":"28","author":"EA Kerr","year":"2012","unstructured":"Kerr EA, Lucatorto MA, Holleman R, Hogan MM, Klamerus ML, Hofer TP, et al. Monitoring performance for blood pressure management among patients with diabetes mellitus: Too much of a good thing? Arch Intern Med. 2012;28:1\u20138.","journal-title":"Arch Intern Med"},{"issue":"3 Suppl","key":"2340_CR20","doi-asserted-by":"publisher","first-page":"146S","DOI":"10.1177\/1077558703257000","volume":"60","author":"W Yu","year":"2003","unstructured":"Yu W, Ravelo A, Wagner TH, Phibbs CS, Bhandari A, Chen S, et al. Prevalence and costs of chronic conditions in the VA health care system. Med Care Res Rev. 2003;60(3 Suppl):146S\u201367.","journal-title":"Med Care Res Rev"},{"issue":"10","key":"2340_CR21","doi-asserted-by":"publisher","first-page":"717","DOI":"10.7326\/0003-4819-148-10-200805200-00004","volume":"148","author":"EA Kerr","year":"2008","unstructured":"Kerr EA, Zikmund-Fisher BJ, Klamerus ML, Subramanian U, Hogan MM, Hofer TP. The role of clinical uncertainty in treatment decisions for diabetic patients with uncontrolled blood pressure. Ann Intern Med. 2008;148(10):717\u201327.","journal-title":"Ann Intern Med"},{"issue":"3","key":"2340_CR22","doi-asserted-by":"publisher","first-page":"725","DOI":"10.2337\/diacare.29.03.06.dc05-2078","volume":"29","author":"JD Piette","year":"2006","unstructured":"Piette JD, Kerr EA. The impact of comorbid chronic conditions on diabetes care. Diabetes Care. 2006;29(3):725\u201331.","journal-title":"Diabetes Care"},{"key":"2340_CR23","unstructured":"Beard AJ, Hofer TP, Lucatorto M, Downs JR, Klamerus ML, Holleman R, et al. Assessing appropriateness of lipid management among patients with diabetes: Moving from target to treatment. (in press, Circulation: Cardiovascular Quality and Outcomes)."},{"issue":"7","key":"2340_CR24","doi-asserted-by":"publisher","first-page":"1651","DOI":"10.2337\/dc11-0735","volume":"34","author":"PJ O\u2019Connor","year":"2011","unstructured":"O\u2019Connor PJ, Bodkin NL, Fradkin J, Glasgow RE, Greenfield S, Gregg E, et al. Diabetes performance measures: current status and future directions. Diabetes Care. 2011;34(7):1651\u20139.","journal-title":"Diabetes Care"},{"issue":"9607","key":"2340_CR25","doi-asserted-by":"publisher","first-page":"117","DOI":"10.1016\/S0140-6736(08)60104-X","volume":"371","author":"PM Kearney","year":"2008","unstructured":"Cholesterol Treatment Trialists\u2019 (CTT) Collaborators, Kearney PM, Blackwell L, Collins R, Keech A, Simes J, et al. Efficacy of cholesterol-lowering therapy in 18,686 people with diabetes in 14 randomised trials of statins: a meta-analysis. Lancet. 2008;371(9607):117\u201325.","journal-title":"Lancet"},{"issue":"9374","key":"2340_CR26","doi-asserted-by":"publisher","first-page":"2005","DOI":"10.1016\/S0140-6736(03)13636-7","volume":"361","author":"R Collins","year":"2003","unstructured":"Collins R, Armitage J, Parish S, Sleigh P, Peto R. Heart Protection Study Collaborative Group. MRC\/BHF Heart Protection Study of cholesterol-lowering with simvastatin in 5963 people with diabetes: a randomised placebo-controlled trial. Lancet. 2003;361(9374):2005\u201316.","journal-title":"Lancet"},{"issue":"9326","key":"2340_CR27","doi-asserted-by":"publisher","first-page":"7","DOI":"10.1016\/S0140-6736(02)09327-3","volume":"360","author":"Heart Protection Study Collaborative Group","year":"2002","unstructured":"Heart Protection Study Collaborative Group. MRC\/BHF heart protection study of cholesterol lowering with simvastatin in 20,536 high-risk individuals: a randomised placebo-controlled trial. Lancet. 2002;360(9326):7\u201322.","journal-title":"Lancet"},{"issue":"9435","key":"2340_CR28","doi-asserted-by":"publisher","first-page":"685","DOI":"10.1016\/S0140-6736(04)16895-5","volume":"364","author":"HM Colhoun","year":"2004","unstructured":"Colhoun HM, Betteridge DJ, Durrington PN, Hitman GA, Neil HA, Livingstone SJ, et al. Primary prevention of cardiovascular disease with atorvastatin in type 2 diabetes in the collaborative atorvastatin diabetes study (CARDS): multicentre randomised placebo-controlled trial. Lancet. 2004;364(9435):685\u201396.","journal-title":"Lancet"},{"issue":"9753","key":"2340_CR29","doi-asserted-by":"publisher","first-page":"1658","DOI":"10.1016\/S0140-6736(10)60310-8","volume":"376","author":"J Armitage","year":"2010","unstructured":"Study of the Effectiveness of Additional Reductions in Cholesterol and Homocysteine (SEARCH) Collaborative Group, Armitage J, Bowman L, Wallendszus K, Bulbulia R, Rahimi K, et al. Intensive lowering of LDL cholesterol with 80\u00a0mg versus 20\u00a0mg simvastatin daily in 12,064 survivors of myocardial infarction: a double-blind randomised trial. Lancet. 2010;376(9753):1658\u201369.","journal-title":"Lancet"},{"issue":"19","key":"2340_CR30","doi-asserted-by":"publisher","first-page":"2437","DOI":"10.1001\/jama.294.19.2437","volume":"294","author":"TR Pedersen","year":"2005","unstructured":"Pedersen TR, Faergeman O, Kastelein JJ, Olsson AG, Tikkanen MJ, Holme I, et al. High-dose atorvastatin vs usual-dose simvastatin for secondary prevention after myocardial infarction: the IDEAL study: a randomized controlled trial. JAMA. 2005;294(19):2437\u201345.","journal-title":"JAMA"},{"issue":"9","key":"2340_CR31","doi-asserted-by":"publisher","first-page":"846","DOI":"10.1097\/00005650-199909000-00002","volume":"37","author":"PW Choo","year":"1999","unstructured":"Choo PW, Rand CS, Inui TS, Lee ML, Cain E, Cordeiro-Breault M, et al. Validation of patient reports, automated pharmacy records, and pill counts with electronic monitoring of adherence to antihypertensive therapy. Med Care. 1999;37(9):846\u201357.","journal-title":"Med Care"},{"issue":"1","key":"2340_CR32","doi-asserted-by":"publisher","first-page":"105","DOI":"10.1016\/S0895-4356(96)00268-5","volume":"50","author":"JF Steiner","year":"1997","unstructured":"Steiner JF, Prochazka AV. The assessment of refill compliance using pharmacy records: methods, validity, and applications. J Clin Epidemiol. 1997;50(1):105\u201316.","journal-title":"J Clin Epidemiol"},{"issue":"8","key":"2340_CR33","doi-asserted-by":"publisher","first-page":"814","DOI":"10.1097\/00005650-198808000-00007","volume":"26","author":"JF Steiner","year":"1988","unstructured":"Steiner JF, Koepsell TD, Fihn SD, Inui TS. A general method of compliance assessment using centralized pharmacy records. description and validation. Med Care. 1988;26(8):814\u201323.","journal-title":"Med Care"},{"issue":"3","key":"2340_CR34","doi-asserted-by":"publisher","first-page":"514","DOI":"10.2337\/diacare.28.3.514","volume":"28","author":"DJ Wexler","year":"2005","unstructured":"Wexler DJ, Grant RW, Meigs JB, Nathan DM, Cagliero E. Sex disparities in treatment of cardiac risk factors in patients with type 2 diabetes. Diabetes Care. 2005;28(3):514\u201320.","journal-title":"Diabetes Care"},{"issue":"3","key":"2340_CR35","first-page":"133","volume":"12","author":"C Kim","year":"2006","unstructured":"Kim C, Kerr EA, Bernstein SJ, Krein SL. Gender disparities in lipid management: the presence of disparities depends on the quality measure. Am J Manage Care. 2006;12(3):133\u20136.","journal-title":"Am J Manage Care"},{"issue":"10","key":"2340_CR36","doi-asserted-by":"publisher","first-page":"1541","DOI":"10.1089\/jwh.2008.1260","volume":"18","author":"J Pregler","year":"2009","unstructured":"Pregler J, Freund KM, Kleinman M, Phipps MG, Fife RS, Gams B, et al. The heart truth professional education campaign on women and heart disease: needs assessment and evaluation results. J Women\u2019s Health (Larchmt). 2009;18(10):1541\u20137.","journal-title":"J Women\u2019s Health (Larchmt)"},{"issue":"18","key":"2340_CR37","doi-asserted-by":"publisher","first-page":"2973","DOI":"10.1517\/14656560903376186","volume":"10","author":"TR Bates","year":"2009","unstructured":"Bates TR, Connaughton VM, Watts GF. Non-adherence to statin therapy: a major challenge for preventive cardiology. Expert Opin Pharmacother. 2009;10(18):2973\u201385.","journal-title":"Expert Opin Pharmacother"},{"issue":"11","key":"2340_CR38","doi-asserted-by":"publisher","first-page":"1256","DOI":"10.1016\/j.amjmed.2005.08.006","volume":"118","author":"DP Nau","year":"2005","unstructured":"Nau DP, Ellis JJ, Kline-Rogers EM, Mallya U, Eagle KA, Erickson SR. Gender and perceived severity of cardiac disease: evidence that women are \u201ctougher\u201d. Am J Med. 2005;118(11):1256\u201361.","journal-title":"Am J Med"},{"issue":"2","key":"2340_CR39","doi-asserted-by":"publisher","first-page":"120","DOI":"10.1161\/CIRCOUTCOMES.109.915538","volume":"3","author":"L Mosca","year":"2010","unstructured":"Mosca L, Mochari-Greenberger H, Dolor RJ, Newby LK, Robb KJ. Twelve-year follow-up of American women\u2019s awareness of cardiovascular disease risk and barriers to heart health. Circ Cardiovasc Qual Outcomes. 2010;3(2):120\u20137.","journal-title":"Circ Cardiovasc Qual Outcomes"},{"issue":"1","key":"2340_CR40","doi-asserted-by":"crossref","first-page":"4","DOI":"10.7812\/TPP\/09-090","volume":"14","author":"V Fung","year":"2010","unstructured":"Fung V, Sinclair F, Wang H, Dailey D, Hsu J, Shaber R. Patients\u2019 Perspectives on nonadherence to statin therapy: a focus-group study. Perm J. 2010;14(1):4\u201310.","journal-title":"Perm J"},{"issue":"1","key":"2340_CR41","doi-asserted-by":"publisher","first-page":"7","DOI":"10.1016\/j.atherosclerosis.2006.10.001","volume":"195","author":"DN Kiortsis","year":"2007","unstructured":"Kiortsis DN, Filippatos TD, Mikhailidis DP, Elisaf MS, Liberopoulos EN. Statin-associated adverse effects beyond muscle and liver toxicity. Atherosclerosis. 2007;195(1):7\u201316.","journal-title":"Atherosclerosis"},{"issue":"9","key":"2340_CR42","doi-asserted-by":"publisher","first-page":"1410","DOI":"10.1345\/aph.1P150","volume":"44","author":"DM Mann","year":"2010","unstructured":"Mann DM, Woodward M, Muntner P, Falzon L, Kronish I. Predictors of nonadherence to statins: a systematic review and meta-analysis. Ann Pharmacother. 2010;44(9):1410\u201321.","journal-title":"Ann Pharmacother"},{"issue":"6","key":"2340_CR43","doi-asserted-by":"publisher","first-page":"572","DOI":"10.1016\/j.jacc.2011.09.067","volume":"59","author":"WJ Kostis","year":"2012","unstructured":"Kostis WJ, Cheng JQ, Dobrzynski JM, Cabrera J, Kostis JB. Meta-analysis of statin effects in women versus men. J Am Coll Cardiol. 2012;59(6):572\u201382.","journal-title":"J Am Coll Cardiol"},{"issue":"9346","key":"2340_CR44","doi-asserted-by":"publisher","first-page":"1623","DOI":"10.1016\/S0140-6736(02)11600-X","volume":"360","author":"J Shepherd","year":"2002","unstructured":"Shepherd J, Blauw GJ, Murphy MB, Bollen EL, Buckley BM, Cobbe SM, et al. Pravastatin in elderly individuals at risk of vascular disease (PROSPER): a randomised controlled trial. Lancet. 2002;360(9346):1623\u201330.","journal-title":"Lancet"},{"issue":"5","key":"2340_CR45","doi-asserted-by":"publisher","first-page":"640","DOI":"10.1111\/j.1365-2125.2003.02060.x","volume":"57","author":"BM Cheung","year":"2004","unstructured":"Cheung BM, Lauder IJ, Lau CP, Kumana CR. Meta-analysis of large randomized controlled trials to evaluate the impact of statins on cardiovascular outcomes. Br J Clin Pharmacol. 2004;57(5):640\u201351.","journal-title":"Br J Clin Pharmacol"},{"key":"2340_CR46","doi-asserted-by":"publisher","first-page":"506","DOI":"10.1001\/archfami.9.6.506","volume":"9","author":"L Mosca","year":"2000","unstructured":"Mosca L, Jones W, King K, Ouyang P, Redberg R, Hill M. Awareness, perception, and knowledge of heart disease risk and prevention among women in the United States. American Heart Association Women\u2019s Heart Disease and Stroke Campaign Task Force. Arch Fam Med. 2000;9:506\u201315.","journal-title":"Arch Fam Med"},{"key":"2340_CR47","doi-asserted-by":"publisher","first-page":"177","DOI":"10.1016\/S0749-3797(01)00348-8","volume":"21","author":"G Cooper","year":"2001","unstructured":"Cooper G, Goodwin M, Stange K. The delivery of preventive services for patient symptoms. Am J Prev Med. 2001;21:177\u201381.","journal-title":"Am J Prev Med"},{"key":"2340_CR48","doi-asserted-by":"publisher","first-page":"167","DOI":"10.1006\/pmed.2000.0700","volume":"31","author":"K Stange","year":"2000","unstructured":"Stange K, Flocke S, Goodwin M, Kelly R, Zyzanski S. Direct observation of rates of preventive service delivery in community family practice. Prev Med. 2000;31:167\u201376.","journal-title":"Prev Med"},{"key":"2340_CR49","doi-asserted-by":"publisher","first-page":"c2197","DOI":"10.1136\/bmj.c2197","volume":"340","author":"J Hippisley-Cox","year":"2010","unstructured":"Hippisley-Cox J, Coupland C. Unintended effects of statins in men and women in England and Wales: population based cohort study using the QResearch database. BMJ. 2010;340:c2197.","journal-title":"BMJ"},{"issue":"4","key":"2340_CR50","doi-asserted-by":"publisher","first-page":"268","DOI":"10.1080\/14017430801993180","volume":"42","author":"H Rosenberg","year":"2008","unstructured":"Rosenberg H, Allard D. Women and statin use: a women\u2019s health advocacy perspective. Scand Cardiovasc J. 2008;42(4):268\u201373.","journal-title":"Scand Cardiovasc J"},{"key":"2340_CR51","doi-asserted-by":"publisher","first-page":"2556","DOI":"10.1001\/jama.2011.860","volume":"24","author":"D Preiss","year":"2011","unstructured":"Preiss D, Seshasai SRK, Welsh P, et al. Risk of incident diabetes with intensive-dose compared with moderate-dose statin therapy: a meta-analysis. JAMA. 2011;24:2556\u201364.","journal-title":"JAMA"},{"key":"2340_CR52","unstructured":"VA Pharmacy Benefits Management. Statin Criteria for Use (Pravastatin, Rosuvastatin, Atorvastatin, Fluvastatin, Fluvastatin XL); VHA Pharmacy Benefits Management (PBM) Services, Medical Advisory Panel (MAP) and VISN Pharmacist Executives (VPEs); 2011. Accessed May 8, 2012, at http:\/\/www.pbm.va.gov."},{"issue":"15","key":"2340_CR53","doi-asserted-by":"publisher","first-page":"1495","DOI":"10.1056\/NEJMoa040583","volume":"350","author":"CP Cannon","year":"2004","unstructured":"Cannon CP, Braunwald E, McCabe CH, et al. Intensive versus moderate lipid lowering with statins after acute coronary syndromes. NEJM. 2004;350(15):1495\u2013504.","journal-title":"NEJM"},{"key":"2340_CR54","doi-asserted-by":"publisher","first-page":"438","DOI":"10.1016\/j.jacc.2006.04.070","volume":"48","author":"CP Cannon","year":"2006","unstructured":"Cannon CP, Steinberg BA, Murphy SA, et al. Meta-analysis of cardiovascular outcomes trials comparing intensive versus moderate statin therapy. J Am Coll Cardiol. 2006;48:438\u201345.","journal-title":"J Am Coll Cardiol"}],"container-title":["Journal of General Internal Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11606-013-2340-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s11606-013-2340-5\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s11606-013-2340-5","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11606-013-2340-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,9,2]],"date-time":"2021-09-02T00:26:08Z","timestamp":1630542368000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s11606-013-2340-5"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2013,6,27]]},"references-count":54,"journal-issue":{"issue":"S2","published-print":{"date-parts":[[2013,7]]}},"alternative-id":["2340"],"URL":"https:\/\/doi.org\/10.1007\/s11606-013-2340-5","relation":{},"ISSN":["0884-8734","1525-1497"],"issn-type":[{"value":"0884-8734","type":"print"},{"value":"1525-1497","type":"electronic"}],"subject":[],"published":{"date-parts":[[2013,6,27]]},"assertion":[{"value":"27 June 2013","order":1,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}}]}}